RxDoctor Payments Data

Stephanie Salzer

Physician Assistant · Metairie, LANPI 1245935501

Payments from drug & device makers

$4,179in general payments, 2019–2025

Across 232 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$913
  • Argenx US, Inc.$373
  • UCB, Inc.$365
  • Pfizer$304
  • Lilly USA, LLC$298
  • Acadia Pharmaceuticals Inc$246
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,179100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,179 in reported general payments places this provider in the 90th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$16,019
Medicare patients
102
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab11$113,563
QuliptaAtogepant39$54,453
UbrelvyUbrogepant41$51,123
Nurtec OdtRimegepant Sulfate14$21,648
Aimovig AutoinjectorErenumab-Aooe18$13,466
Emgality PenGalcanezumab-Gnlm17$10,861
RytaryCarbidopa/Levodopa11$6,252
Lacosamide30$2,321
Gabapentin121$1,336
Carbidopa-LevodopaCarbidopa/Levodopa70$1,120
Memantine Hcl81$1,105
Levetiracetam40$737
Primidone32$734
Donepezil Hcl80$422
Quetiapine Fumarate32$358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$913$105,57680 claims
PfizerNurtec Odt$304$21,64814 claims
Amneal Pharmaceuticals LLCRytary$74$6,25211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →